Literature DB >> 24812054

Epiregulin promotes the emergence and proliferation of adult liver progenitor cells.

Kyoko Tomita1, Hiroaki Haga2, Kei Mizuno3, Tomohiro Katsumi2, Chikako Sato3, Kazuo Okumoto2, Yuko Nishise2, Hisayoshi Watanabe3, Takafumi Saito2, Yoshiyuki Ueno3.   

Abstract

We have previously reported that epiregulin is a growth factor that seems to act on liver progenitor cells (LPCs) during liver regeneration. However, the relationship between epiregulin and LPCs has remained unclear. The aim of the present study was to clarify the role of epiregulin during liver regeneration. The serum levels of epiregulin in patients with acute liver failure were examined. A liver injury model was developed using mice fed a diet containing 0.1% 3.5-diethoxycarbonyl-1.4-dihydrocollidine (DDC) to induce LPCs. We then evaluated the expression of epiregulin and LPCs in these mice. The proliferation of epithelial cell adhesion molecule + LPCs cultured with epiregulin was examined in vitro, and finally epiregulin was overexpressed in mouse liver. In patients with acute liver failure, serum epiregulin levels were elevated significantly. In DDC mice, LPCs emerged around the portal area. Epiregulin was also detected around the portal area during the course of DDC-induced liver injury and was partially coexpressed with Thy1. Serum epiregulin levels in DDC mice were also significantly elevated. Recombinant epiregulin augmented the proliferative capacity of the LPCs in a dose-dependent manner. In mice showing overexpression of epiregulin, the expression of PCNA on hepatocytes was increased significantly. Finally, LPCs emerged around the portal area after epiregulin gene delivery. We concluded that epiregulin promotes the proliferation of LPCs and DNA synthesis by hepatocytes and is upregulated in the serum of patients with liver injury. Furthermore, induction of epiregulin leads to the appearance of LPCs. Epiregulin would be a useful biomarker of liver regeneration.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  Thy1; epiregulin; epithelial cell adhesion molecule; liver injury; liver regeneration; progenitor cells

Mesh:

Substances:

Year:  2014        PMID: 24812054     DOI: 10.1152/ajpgi.00434.2013

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  6 in total

1.  Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.

Authors:  Alison K Bauer; Kalpana Velmurugan; Ka-Na Xiong; Carla-Maria Alexander; Julie Xiong; Rana Brooks
Journal:  Mol Carcinog       Date:  2016-02-19       Impact factor: 4.784

2.  The homeostatic malfunction of a novel feedback pathway formed by lncRNA021545, miR-330-3p and epiregulin contributes in hepatocarcinoma progression via mediating epithelial-mesenchymal transition.

Authors:  Siwen Yang; Yunkun Zhang; Chunmei Guo; Rui Liu; Maroua Elkharti; Zhenhua Ge; Qinlong Liu; Shuqing Liu; Ming-Zhong Sun
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

Review 3.  Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant.

Authors:  Hon Jen Wong; Wen Hui Lim; Cheng Han Ng; Darren Jun Hao Tan; Glenn K Bonney; Alfred W C Kow; Daniel Q Huang; Mohammad Shadab Siddiqui; Mazen Noureddin; Nicholas Syn; Mark D Muthiah
Journal:  Front Med (Lausanne)       Date:  2022-05-10

Review 4.  EGFR Signaling in Liver Diseases.

Authors:  Karin Komposch; Maria Sibilia
Journal:  Int J Mol Sci       Date:  2015-12-29       Impact factor: 5.923

Review 5.  EGF receptor ligands: recent advances.

Authors:  Bhuminder Singh; Graham Carpenter; Robert J Coffey
Journal:  F1000Res       Date:  2016-09-08

6.  Epiregulin enhances odontoblastic differentiation of dental pulp stem cells via activating MAPK signalling pathway.

Authors:  Dixin Cui; Jiani Xiao; Yachuan Zhou; Xin Zhou; Ying Liu; Yiran Peng; Yi Yu; Hongyu Li; Xuedong Zhou; Quan Yuan; Mian Wan; Liwei Zheng
Journal:  Cell Prolif       Date:  2019-08-27       Impact factor: 6.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.